Breast  ||| S:0 E:7 ||| JJ
cancer  ||| S:7 E:14 ||| NN
mortality  ||| S:14 E:24 ||| NN
in  ||| S:24 E:27 ||| IN
Mexico ||| S:27 E:33 ||| NNP
:  ||| S:33 E:35 ||| :
an  ||| S:35 E:38 ||| DT
age-period-cohort  ||| S:38 E:56 ||| JJ
analysis  ||| S:56 E:65 ||| NN
To  ||| S:65 E:68 ||| TO
assess  ||| S:68 E:75 ||| VB
the  ||| S:75 E:79 ||| DT
age ||| S:79 E:82 ||| NN
,  ||| S:82 E:84 ||| ,
period  ||| S:84 E:91 ||| NN
and  ||| S:91 E:95 ||| CC
cohort  ||| S:95 E:102 ||| JJ
effects  ||| S:102 E:110 ||| NNS
on  ||| S:110 E:113 ||| IN
breast  ||| S:113 E:120 ||| JJ
cancer  ||| S:120 E:127 ||| NN
( ||| S:127 E:128 ||| -LRB-
BC ||| S:128 E:130 ||| NNP
)  ||| S:130 E:132 ||| -RRB-
mortality  ||| S:132 E:142 ||| NN
in  ||| S:142 E:145 ||| IN
Mexico ||| S:145 E:151 ||| NNP
.  ||| S:151 E:153 ||| .
Age ||| S:153 E:156 ||| NN
,  ||| S:156 E:158 ||| ,
period  ||| S:158 E:165 ||| NN
and  ||| S:165 E:169 ||| CC
cohort  ||| S:169 E:176 ||| JJ
curvature  ||| S:176 E:186 ||| JJ
trends  ||| S:186 E:193 ||| NNS
for  ||| S:193 E:197 ||| IN
BC  ||| S:197 E:200 ||| NNP
mortality  ||| S:200 E:210 ||| NN
were  ||| S:210 E:215 ||| VBD
estimated  ||| S:215 E:225 ||| VBN
through  ||| S:225 E:233 ||| IN
the  ||| S:233 E:237 ||| DT
Poisson  ||| S:237 E:245 ||| NNP
Regression  ||| S:245 E:256 ||| NNP
model  ||| S:256 E:262 ||| NN
proposed  ||| S:262 E:271 ||| VBN
by  ||| S:271 E:274 ||| IN
Holford ||| S:274 E:281 ||| NNP
.  ||| S:281 E:283 ||| .
Nationally ||| S:283 E:293 ||| RB
,  ||| S:293 E:295 ||| ,
BC  ||| S:295 E:298 ||| NNP
death  ||| S:298 E:304 ||| NN
rates  ||| S:304 E:310 ||| NNS
have  ||| S:310 E:315 ||| VBP
leveled  ||| S:315 E:323 ||| VBN
off  ||| S:323 E:327 ||| RP
since  ||| S:327 E:333 ||| IN
1995  ||| S:333 E:338 ||| CD
in  ||| S:338 E:341 ||| IN
most  ||| S:341 E:346 ||| JJS
age  ||| S:346 E:350 ||| NN
groups ||| S:350 E:356 ||| NNS
.  ||| S:356 E:358 ||| .
BC  ||| S:358 E:361 ||| NNP
mortality  ||| S:361 E:371 ||| NN
trends  ||| S:371 E:378 ||| NNS
are  ||| S:378 E:382 ||| VBP
mainly  ||| S:382 E:389 ||| RB
determined  ||| S:389 E:400 ||| VBN
by  ||| S:400 E:403 ||| IN
birth  ||| S:403 E:409 ||| NN
cohort  ||| S:409 E:416 ||| NNS
and  ||| S:416 E:420 ||| CC
age  ||| S:420 E:424 ||| NN
effects  ||| S:424 E:432 ||| NNS
in  ||| S:432 E:435 ||| IN
Mexico ||| S:435 E:441 ||| NNP
.  ||| S:441 E:443 ||| .
Women  ||| S:443 E:449 ||| NNS
born  ||| S:449 E:454 ||| VBN
between  ||| S:454 E:462 ||| IN
1940  ||| S:462 E:467 ||| CD
and  ||| S:467 E:471 ||| CC
1955  ||| S:471 E:476 ||| CD
show  ||| S:476 E:481 ||| NN
the  ||| S:481 E:485 ||| DT
highest  ||| S:485 E:493 ||| JJS
rate  ||| S:493 E:498 ||| NN
of  ||| S:498 E:501 ||| IN
increase  ||| S:501 E:510 ||| NN
in  ||| S:510 E:513 ||| IN
BC  ||| S:513 E:516 ||| NNP
mortality ||| S:516 E:525 ||| NN
.  ||| S:525 E:527 ||| .
Women  ||| S:527 E:533 ||| NNS
born  ||| S:533 E:538 ||| VBN
afterwards  ||| S:538 E:549 ||| RB
still  ||| S:549 E:555 ||| RB
show  ||| S:555 E:560 ||| VB
an  ||| S:560 E:563 ||| DT
increasing  ||| S:563 E:574 ||| JJ
trend  ||| S:574 E:580 ||| NN
but  ||| S:580 E:584 ||| CC
at  ||| S:584 E:587 ||| IN
a  ||| S:587 E:589 ||| DT
much  ||| S:589 E:594 ||| RB
lower  ||| S:594 E:600 ||| JJR
rate ||| S:600 E:604 ||| NN
.  ||| S:604 E:606 ||| .
Mammography  ||| S:606 E:618 ||| NNP
and  ||| S:618 E:622 ||| CC
adjuvant  ||| S:622 E:631 ||| JJ
therapy  ||| S:631 E:639 ||| NN
have  ||| S:639 E:644 ||| VBP
had  ||| S:644 E:648 ||| VBN
a  ||| S:648 E:650 ||| DT
limited  ||| S:650 E:658 ||| JJ
impact  ||| S:658 E:665 ||| NN
on  ||| S:665 E:668 ||| IN
mortality ||| S:668 E:677 ||| NN
.  ||| S:677 E:679 ||| .
Potential  ||| S:679 E:689 ||| JJ
reasons  ||| S:689 E:697 ||| NNS
for  ||| S:697 E:701 ||| IN
observed  ||| S:701 E:710 ||| JJ
patterns  ||| S:710 E:719 ||| NNS
are  ||| S:719 E:723 ||| VBP
discussed ||| S:723 E:732 ||| VBN
.  ||| S:732 E:734 ||| .
An  ||| S:734 E:737 ||| DT
increase  ||| S:737 E:746 ||| NN
in  ||| S:746 E:749 ||| IN
BC  ||| S:749 E:752 ||| NNP
mortality  ||| S:752 E:762 ||| NN
in  ||| S:762 E:765 ||| IN
Mexico  ||| S:765 E:772 ||| NNP
is  ||| S:772 E:775 ||| VBZ
expected  ||| S:775 E:784 ||| VBN
in  ||| S:784 E:787 ||| IN
the  ||| S:787 E:791 ||| DT
following  ||| S:791 E:801 ||| JJ
decades ||| S:801 E:808 ||| NNS
.  ||| S:808 E:810 ||| .
Mammography  ||| S:810 E:822 ||| JJ
screening  ||| S:822 E:832 ||| NN
programs  ||| S:832 E:841 ||| NNS
and  ||| S:841 E:845 ||| CC
timely  ||| S:845 E:852 ||| JJ
access  ||| S:852 E:859 ||| NN
to  ||| S:859 E:862 ||| TO
effective  ||| S:862 E:872 ||| JJ
treatment  ||| S:872 E:882 ||| NN
should  ||| S:882 E:889 ||| MD
be  ||| S:889 E:892 ||| VB
a  ||| S:892 E:894 ||| DT
national  ||| S:894 E:903 ||| JJ
priority  ||| S:903 E:912 ||| NN
to  ||| S:912 E:915 ||| TO
reverse  ||| S:915 E:923 ||| VB
the  ||| S:923 E:927 ||| DT
expected  ||| S:927 E:936 ||| VBN
increasing  ||| S:936 E:947 ||| VBG
BC  ||| S:947 E:950 ||| NNP
mortality  ||| S:950 E:960 ||| NN
trend ||| S:960 E:965 ||| NN
.  ||| S:965 E:967 ||| .
